Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
NCT ID: NCT01888744
Last Updated: 2013-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
120 participants
INTERVENTIONAL
2010-09-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (GnRH agonist group)
The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels \< 80 pg/ml, FSH ≤ 10 IU/l and progesterone \< 1,5ng/ml)
GnRH agonist
hP-hMG
Human chorionic gonadotropin
induction of final oocyte maturation
Progesterone
Group 2 (GnRH antagonist group)
Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
GnRH antagonist
hP-hMG
Human chorionic gonadotropin
induction of final oocyte maturation
Progesterone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GnRH agonist
GnRH antagonist
hP-hMG
Human chorionic gonadotropin
induction of final oocyte maturation
Progesterone
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≤ 29
* cycle rank 1
* menstrual cycle 25-36 days
* PGD or preimplantation genetic screening (PGS) requested
* ICSI
* Single embryo transfer (SET) on day 5
Exclusion Criteria
* Hormonal disturbances
* Endometriosis grade III and IV
18 Years
39 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christophe Blockeel
Professor Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Reproductive Medicine
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010/010
Identifier Type: -
Identifier Source: org_study_id